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M A J O R A R T I C L E
Risk of Stroke Following Herpes Zoster:
A Self-Controlled Case-Series Study
Sinéad M. Langan,a Caroline Minassian,a Liam Smeeth, and Sara L. Thomas
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, United Kingdom
(See the Editorial Commentary by Nagel and Gilden on pages 1504–6.)
Background. Herpes zoster is common and vaccine preventable. Stroke risk may be increased following zoster,
but evidence is sparse and could be explained by differences between people with and without zoster. Our objective
was to determine if stroke risk is increased following zoster.
Methods. Within-person comparisons were undertaken using the self-controlled case-series method and data
from the UK Clinical Practice Research Datalink (1987–2012). Participants had a ﬁrst-ever diagnosis of zoster and
stroke within the study period. Stroke incidence in periods following zoster was compared with incidence in other
time periods. Age-adjusted incidence ratios (IRs) and 95% conﬁdence intervals (CIs) were calculated.
Results. A total of 6584 individuals were included. Stroke rate was increased following zoster compared with the
baseline unexposed period, then gradually reduced over 6 months: weeks 1–4 (age-adjusted IR, 1.63; 95% CI, 1.32–
2.02), weeks 5–12 (IR, 1.42; 95% CI, 1.21–1.68), and weeks 13–26 (IR, 1.23; 95% CI, 1.07–1.42), with no increase
thereafter. A stronger effect was observed for individuals with zoster ophthalmicus, rising to a >3-fold rate 5–12
weeks after zoster. Oral antivirals were given to 55% of individuals: IRs for stroke were lower among those receiving
antivirals compared with those not treated, suggesting a protective effect.
Conclusions. We have established an increased stroke rate within 6 months following zoster. Findings have impli-
cations for zoster vaccination programs, which may reduce stroke risk following zoster. The low antiviral prescribing
rate needs to be improved; our data suggest that antiviral therapy may lead to a reduced stroke risk following zoster.
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There is mounting epidemiological evidence from dif-
ferent populations using different study designs of
strong associations between acute systemic infections
and risk of acute vascular events [1, 2]. It is believed
that the transient increase in risk relates to endothelial
dysfunction on a background of arteriopathy with pla-
que rupture and hypercoagulability [3]. The effect of
speciﬁc infections on acute vascular events including
stroke has been less explored.
Herpes zoster is a signiﬁcant public health problem
in aging populations, affecting 1 million Americans
per year and >88 650 immunocompetent people aged
>60 years annually in the United Kingdom and result-
ing in signiﬁcant complications [4–6]. It occurs follow-
ing reactivation of latent varicella zoster virus (VZV)
infection. The initial presentation consists of a painful
vesicular rash that can lead to prolonged pain and post-
herpetic neuralgia (PHN), with a major impact on qual-
ity of life [5]. The importance of zoster and associated
complications are reﬂected by the introduction of major
adult vaccination programs in the United States, United
Kingdom, and elsewhere to prevent disease.
In addition to systemic inﬂammation after the acute
reactivation of dormant VZV infection, zoster could in-
crease stroke risk by viral invasion of arterial walls and
induction of vasculopathy [7].Case reports have report-
ed strokes following zoster [8, 9]. Two cohort studies of
adults from Taiwan showed a 1.3-fold (95% conﬁdence
interval [CI], 1.1- to 1.6-fold) and 4.5-fold (95%CI, 2.5- to
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8.3-fold) increased risk of stroke in the year following zoster and
herpes zoster opthalmicus, respectively [10, 11].However, effect
estimates were not adjusted for key confounders including body
mass index and atrial ﬁbrillation [12]. It could be that the ob-
served increased risk of stroke following zostermay be entirely due
to residual confounding. Thus, rigorous epidemiological studies
that deal with confounding are needed to determine if there is
an increased risk of stroke following zoster. Such an effect, if gen-
uine, would have important implications for targeting zoster vac-
cination programs. We set out to determine if adults experiencing
zoster at any site or herpes zoster ophthalmicus are at increased
risk of stroke within 12 months after zoster using a novel method
that inherently avoids between-person confounding, the self-
controlled case series (SCCS) method. We also examined whether
the effect was modiﬁed by receipt of antiviral therapy.
METHODS
Ethics Approval
Ethics approval was obtained from the Independent Scientiﬁc
Advisory Committee of the Clinical Practice Research Datalink
(CPRD; formerly GPRD) and the Ethics Committee of the
London School of Hygiene and Tropical Medicine.
Data Source
The CPRD is the world’s largest computerized database of ano-
nymized longitudinal patient records from general practice,
containing data on approximately 8% of the UK population.
Data are obtained from >625 general practices for a currently
registered population of >5 million people representative of
the general UK population [13]. The data contain complete
medical records including prescriptions and feedback from re-
ferrals and hospitalizations. CPRD data have been widely used
for epidemiological research, and studies conﬁrm the validity of
stroke diagnoses in this data source [14–17].A proportion of in-
dividuals in CPRD are linked to Hospital Episode Statistics
(HES), containing details of admissions to National Health Ser-
vices hospitals in England. The HES-CPRD link provides infor-
mation on patients hospitalized from 1997 onward.
Study Design
This study estimated stroke risk following an acute episode of
zoster. Critical differences between those who develop and do
not develop zoster are difﬁcult to capture in many observational
study designs, leading to residual confounding. The SCCS
method compares risks during different time periods within in-
dividuals. Thus, risks are compared in the period following zos-
ter to other “unexposed” time periods (Figure 1). The major
advantage of SCCS for our research question is that it avoids be-
tween-person confounding (due to differing stroke risk among
individuals with and without zoster) [18]. The null hypothesis
was that stroke risk is not increased following zoster infection.
Participants
All adults (aged ≥18 years) with evidence of incident zoster and
an incident stroke were identiﬁed. Follow-up began at the later
of the date that an individual registered with a practice or the
date that the individual’s practice met established quality stan-
dards. Follow-up ended when the individual left his/her practice
Figure 1. Pictorial representation of the self-controlled case series study.
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or died, or the practice left the database. To ensure observation
of incident rather than prevalent or past zoster and stroke, the
study period (observation period for incident events) began 12
months after the start of follow-up [19]. To restrict to ﬁrst-ever
episodes of incident zoster and stroke, we excluded individuals
with evidence of zoster, PHN, or stroke before the study period.
As our major interest was in incident arterial strokes, we addi-
tionally excluded individuals whose incident episode was a tran-
sient ischemic attack (TIA) and those with subarachnoid
hemorrhage or with speciﬁc established risk factors for subar-
achnoid hemorrhage, such as cerebral aneurysms in the circle of
Willis or arteriovenous malformations. Zoster can occasionally
lead to cerebral aneurysms by damaging vessel walls; hence, in-
dividuals with nonspeciﬁc cerebral aneurysms were not exclud-
ed from the study [7]. Individuals with a record of encephalitis
within 12 months after stroke were excluded, as these may rep-
resent encephalitis initially misdiagnosed as stroke.
Exposure and Outcome
First-ever incident zoster and arterial stroke were identiﬁed
from CPRD and, in those with linked data, from hospital record
primary diagnoses using Read and International Classiﬁcation
of Diseases, Tenth Revision (ICD-10) diagnostic codes, respec-
tively. Herpes zoster ophthalmicus was identiﬁed from the pres-
ence of speciﬁc diagnostic codes, or, when the zoster codes were
nonspeciﬁc, from diagnoses of or treatments for acute eye infec-
tion within 2 weeks of zoster onset or from records of ﬁrst-ever
speciﬁc nonacute eye conditions known to be associated with
zoster (eg, conjunctival scarring or episcleritis), within 3
months after zoster onset. Oral antiviral treatments were iden-
tiﬁed from therapy records 1 week before and up to 2 weeks
after incident zoster.
Stroke episodes were created whereby diagnostic codes for
stroke or TIA within 28 days of each other were considered
part of the same episode. This method facilitated differentiation
of the type of stroke (cerebral infarction, hemorrhagic stroke, or
stroke of unspeciﬁed type) and between stroke and TIA (when
all records in an episode were TIA), for later exclusion of TIA.
An important assumption of the SCCS method is that recurrent
outcome events must be independent, that is, the occurrence of
1 event must not alter the probability of a subsequent event
occurring. Because having 1 stroke may increase the risk of a
further stroke, only the date of onset of the ﬁrst stroke for
each individual was included in the study [20].
Analysis
The exposed period started the day after incident zoster and ex-
tended to 12 months, subdivided into weeks 1–4, 5–12, 13–26,
and 27–52 following zoster. All other observation time made up
the baseline (unexposed) period, with the exception of the day
of zoster (stroke records on the same day as incident zoster may
be retrospective diagnoses [21]) and the 4-week period prior to
zoster (the chance of developing and presenting with zoster
after an incident stroke may be different from other time peri-
ods; hence, stroke incidence during this time may be lower or
higher than during baseline). The primary analyses assessed
the effect of (1) zoster at any site and (2) zoster ophthalmicus
on stroke (all types). Additional analyses were undertaken for
each stroke type separately (cerebral infarctions, hemorrhagic,
and type-unspeciﬁed strokes). Conditional Poisson regression
was used to calculate incidence ratios (IRs) and 95% conﬁdence
intervals (CIs) for stroke within each stratum of the exposed pe-
riod compared with baseline, adjusting for age in 5-year bands,
with a sensitivity analysis adjusting for 2-year age bands. A fur-
ther stratiﬁed analysis was undertaken to determine if stroke
risk following zoster was different between those who received
and those who did not receive antiviral treatment for zoster.
When using the SCCS method, the occurrence of an event
must not alter the probability of subsequent exposure and
must not censor the observation period. Risk of death is in-
creased following a stroke, removing the possibility of being ex-
posed to zoster and censoring the individual’s follow-up. Hence,
a sensitivity analysis was undertaken excluding individuals who
died or whose follow-up ended within 90 days of their stroke.
Further sensitivity analyses were undertaken to include the
day of zoster in the exposed period, and to restrict to individuals
aged ≥60 years and to patients whose records were linked to
HES (in which date of stroke onset may be better recorded).
Analyses were undertaken using Stata (version 12.0).
RESULTS
Of the 11 997 individuals identiﬁed with ﬁrst-ever zoster and
ﬁrst-ever stroke or TIA within the study period, 6584 fulﬁlled
study inclusion criteria (Supplementary Figure 1). The median
age at stroke was 77 years (interquartile range [IQR], 69–84
years), and 57% were women. The median observation period
was 12.5 years (IQR, 8.7–17.1 years). Most strokes (n = 3944
[60%]) were of unspeciﬁed type, with smaller numbers having
records conﬁrming ischemic (n = 2174 [33%]) and hemorrhag-
ic (n = 422 [6%]) strokes. Most cases had zoster of an unspeci-
ﬁed site (n = 6126 [93%]), 426 (6%) had evidence of herpes
zoster ophthalmicus, and 32 (0.5%) had zoster in other branch-
es of the trigeminal nerve (Table 1). Systemic antiviral therapy
was received in 3647 (55%) study participants.
The overall rate of strokes was signiﬁcantly increased in
weeks 1–4 postzoster compared with baseline (IR, 1.63; 95%
CI, 1.32–2.02) with a slowly diminishing increased rate extend-
ing up to 6 months postzoster: weeks 5–12 (IR, 1.42; 95% CI,
1.21–1.68), and weeks 13–26 (IR, 1.23; 95% CI, 1.07–1.42)
(Tables 2 and 3). An even stronger effect was observed among
individuals not treated with antiviral therapy (weeks 1–4: IR,
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2.14; 95% CI, 1.62–2.84), with a similar pattern of resolution (P
value for interaction = .03) (Table 4). Estimates in weeks 1–4
were nearly double in those not receiving antiviral therapy com-
pared with those receiving treatment. Among individuals treat-
ed with oral antivirals, the only period with increased rate of
stroke compared with baseline was the 5–12 weeks postzoster
(IR, 1.28; 95% CI, 1.02–1.62).
Analyses by zoster site indicated that herpes zoster ophthal-
micus was associated with a stronger effect on stroke overall
(weeks 5–12: IR, 3.38; 95% CI, 2.18–5.24 for herpes zoster oph-
thalmicus and IR, 1.30; 95% CI, 1.09–1.5 for those with site un-
speciﬁed) with nonoverlapping conﬁdence intervals. For herpes
zoster ophthalmicus, the most marked increase was delayed
until weeks 5–12. Similar ﬁndings were observed when combin-
ing individuals with zoster in ophthalmic and other branches of
the trigeminal nerve (Table 3).
Stratifying herpes zoster ophthalmicus analyses by receipt of
oral antivirals also suggested a stronger effect among individuals
who did not receive antiviral treatment, with a >5-fold increase
in the rate of stroke during weeks 5–12 postherpes zoster
ophthalmicus (IR, 5.47; 95% CI, 2.80–10.71). A less marked
(though statistically signiﬁcant) effect was observed among
those receiving antiviral therapy for herpes zoster ophthalmicus
(IR, 2.57; 95% CI, 1.43–4.62, P value for interaction = .33)
(Table 4).
Table 1. Characteristics of 6584 Eligible Patients With Both Zoster and Stroke During the Study Period
Characteristic
All Zoster Cases
(N = 6584)
Zoster Site
Ophthalmic
(n = 426)
Other Trigeminal
(n = 32)
Site Unspecified
(n = 6126)
Age at index strokea, y, median (IQR) 77.0 (68.9–83.8) 78.9 (70.8–84.8) 73.0 (64.6–78.6) 76.9 (68.7–83.7)
Male sex, No. (%) 2813 (42.7) 189 (44.4) 23 (71.9) 2601 (42.5)
Total observation, y, median (IQR)b 12.5 (8.7–17.1) 12.0 (8.5–16.8) 13.9 (8.3–18.5) 12.5 (8.7–17.2)
Eligible for HES, No. (%) 3617 (54.9) 239 (56.1) 15 (46.9) 3363 (54.9)
Type of index stroke, No. (%)
Infarct 2174 (33.0) 145 (34.0) 13 (40.6) 2016 (32.9)
Hemorrhagic 422 (6.4) 21 (4.9) 0 (0) 401 (6.6)
Type unspecified 3944 (59.9) 256 (60.1) 19 (59.4) 3669 (59.9)
Otherc 44 (0.7) 4 (0.9) 0 (0) 40 (0.6)
Abbreviations: HES, Hospital Episode Statistics; IQR, interquartile range.
a First stroke episode in study period.
b Follow-up during study period.
c Stroke episode contained both an infarct and a hemorrhagic stroke code.
Table 2. Age-Adjusted Incidence Ratios for Stroke in Risk
Periods Following Zoster
Outcome and Risk Period No. of Cases IRa (95% CI)
Stroke (all types) 6584
Risk period after zoster
1–4 wk 90 1.63 (1.32–2.02)
5–12 wk 149 1.42 (1.21–1.68)
13–26 wk 215 1.23 (1.07–1.42)
27–52 wk 303 0.99 (.88–1.12)
Abbreviations: CI, confidence interval; IR, incidence ratio.
a Incidence ratio, adjusting for age in 5-year bands.
Table 3. Age-Adjusted Incidence Ratios for Stroke in Risk
Periods Following Zoster, by Site of Zoster
Site of Zoster and Risk Period No. of Cases IRa (95% CI)
Ophthalmic 426
Risk period post zoster
1–4 wk 6 1.82 (.81–4.10)
5–12 wk 22 3.38 (2.18–5.24)
13–26 wk 15 1.39 (.83–2.35)
27–52 wk 16 0.82 (.49–1.36)
Ophthalmic/other trigeminal 458
Risk period postzoster
1–4 wk 6 1.74 (.77–3.91)
5–12 wk 22 3.23 (2.08–4.99)
13–26 wk 16 1.41 (.85–2.33)
27–52 wk 18 0.87 (.54–1.41)
Site unspecified 6126
Risk period postzoster
1–4 wk 84 1.62 (1.30–2.02)
5–12 wk 127 1.30 (1.09–1.55)
13–26 wk 199 1.22 (1.06–1.41)
27–52 wk 285 1.00 (.89–1.13)
Abbreviations: CI, confidence interval; IR, incidence ratio.
a Incidence ratio adjusting for age in 5-year bands.
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Similar increased rates of stroke following zoster were ob-
served for arterial ischemic and hemorrhagic stroke (Supple-
mentary Table 1). Sensitivity analyses including the day of
zoster in the exposed period, and including only individuals
aged ≥60 years, those whose follow-up ended within 90 days
following their stroke (possibly indicating death due to stroke),
or those whose records were linked to HES did not modify study
ﬁndings (data not shown). Sensitivity analysis using 2-year age
bands did not modify study ﬁndings.
DISCUSSION
The key study ﬁnding was that acute zoster is associated with an
increased risk of stroke in the ﬁrst 6 months following zoster.
Risk of incident stroke following zoster was higher for individ-
uals with herpes zoster ophthalmicus or other zoster in the dis-
tribution of the trigeminal nerve. Results also indicated that the
use of oral antiviral therapy to treat acute zoster was associated
with a less marked increase in incident strokes following zoster
exposure. These ﬁndings from a large population-based data
source provide important insights into the temporality and
magnitude of stroke risk increase following zoster.
Two previous cohort studies from Taiwan reported a 30% in-
creased risk of stroke in the year following zoster with a >4-fold
increased risk following herpes zoster ophthalmicus [10, 11].
Neither study adequately addressed key confounders, for exam-
ple, BMI and atrial ﬁbrillation. In addition, these studies did not
assess the timing of increased risk following acute zoster. A re-
cent Danish registry cohort study identiﬁed increased stroke
risks in the ﬁrst year following zoster, particularly within
2 weeks of diagnosis. However, that study had important limi-
tations, including using antiviral treatment as a proxy for zoster
diagnoses and inadequate control for confounding. Hence, the
study assessed the effect of treated zoster on stroke; also, the
exposed group would include off-label prescribing for herpes
simplex virus whereas the unexposed group would include un-
treated individuals with zoster [22].A UK cohort study reported
increased risks of TIA and of stroke in adults of all ages and in
those aged 18–40 years, respectively, during up to 24 years of
follow-up following zoster [5]. This study used a cohort design,
and the results could be prone to residual confounding due to
between-person differences. Additionally, the research question
focused on long-term rather than acute effects of zoster on
stroke.
[11]. Our study has shown a signiﬁcantly increased risk of
stroke following zoster, in particular for zoster in the trigeminal
nerve distribution. Use of the SCCS method is a unique ap-
proach; its major advantage for this study question is that
ﬁxed confounders are implicitly controlled for, as analyses are
within-person. Our ﬁndings have demonstrated that the ﬁrst
Table 4. Age-Adjusted Incidence Ratios for Stroke in Risk Periods Following Zoster, Stratiﬁed by Oral Antiviral Drug Prescriptions
Site of Zoster and Risk Period
Oral Antiviral Prescriptiona No Oral Antiviral Prescription
No. of Cases IRb (95% CI) No. of Cases IRb (95% CI)
Zoster (all) 3647 2937
Risk period post zoster
1–4 wk 38 1.23 (.89–1.71) 52 2.14 (1.62–2.84)
5–12 wk 75 1.28 (1.02–1.62) 74 1.61 (1.27–2.03)
13–26 wk 117 1.19 (.99–1.44) 98 1.29 (1.05–1.58)
27–52 wk 184 1.08 (.93–1.25) 119 0.89 (.74–1.07)
Ophthalmic 299 127
Risk period post zoster
1–4 wk 3 1.26 (.40–3.96) 3 3.27 (1.02–10.44)
5–12 wk 12 2.57 (1.43–4.62) 10 5.47 (2.80–10.71)
13–26 wk 12 1.55 (.86–2.79) 3 1.00 (.31–3.18)
27–52 wk 10 0.70 (.37–1.33) 6 1.12 (.48–2.59)
Site unspecified 3337 2789
Risk period post zoster
1–4 wk 35 1.23 (.88–1.73) 49 2.10 (1.58–2.81)
5–12 wk 63 1.17 (.91–1.51) 64 1.45 (1.13–1.87)
13–26 wk 105 1.16 (.96–1.42) 94 1.29 (1.05–1.59)
27–52 wk 172 1.10 (.94–1.29) 113 0.89 (.73–1.07)
Abbreviations: CI, confidence interval; IR, incidence ratio.
a P values for interaction: zoster overall, P = .03; ophthalmic zoster, P = .33; and site unspecified zoster, P = .03.
b Incidence ratio adjusting for age in 5-year bands.
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3 months postzoster is the key period of increased risk, with res-
olution over the subsequent 3 months.
The biological mechanisms underlying the observed in-
creased risk of stroke following zoster are likely to be multifac-
torial. First, inﬂammation associated with systemic infection
may lead to endothelial dysfunction accompanied by disruption
of atheromatous plaques and hypercoagulability [23]. In addi-
tion, VZV vasculopathy, whereby the VZV virus spreads
along nerve ﬁbers and directly involves the vessels, is highly
likely to be an important mechanism [7]. In support of the
role of VZV vasculopathy is the stronger association between
zoster in the trigeminal nerve and the development of arterial
stroke. VZV vasculopathy could plausibly trigger either ische-
mic or hemorrhagic stroke, with the latter arising as a result
of arterial dissection and aneurysm following vessel wall dam-
age. In our study, stroke risk was increased overall with similar
increases in risk observed for ischemic and hemorrhagic stroke.
Our data suggest a slightly delayed effect for herpes zoster oph-
thalmicus compared with zoster of unspeciﬁed sites; this ﬁnding
is unlikely to be explained by stroke type (Table 1) and may be
explained by small numbers in the herpes zoster ophthalmicus
group, as there is no obvious biological reason for this difference.
The low antiviral prescription rates observed in this study are
consistent with work previously undertaken by our group in
this population [24]. Antiviral therapy may be critically impor-
tant as our study suggests that stroke risk after zoster is lower in
those treated with antiviral therapy than in untreated individu-
als, although this did not reach statistical signiﬁcance in the
smaller subset of ophthalmic zoster patients. The actual dif-
ference in risk between those prescribed and those not pre-
scribed antiviral drugs is likely to be even greater than that we
observed—individuals given antiviral therapy are likely to have
had more severe disease. This differential prescribing of antivi-
ral drugs could introduce confounding by indication, reducing
the perceived beneﬁt of antiviral therapy. It is known that anti-
viral drugs reduce acute pain and zoster severity, accelerate heal-
ing. and may reduce PHN; hence, it follows that antiviral drugs
might have the potential to reduce other postzoster adverse
events, including vascular events, by reducing inﬂammation
[25, 26].
Using the SCCS method, we studied stroke risk following zos-
ter within individuals comparing the risk in exposed periods
following zoster to the risk during unexposed periods; thus, im-
portant differences in baseline risk of stroke between partici-
pants were removed. We controlled for the time-varying effect
of age; residual confounding could only occur if other time-
varying covariates were strongly associated with the timing
of zoster and stroke in many of our study population. The
observed increase in risk of stroke following zoster that rose
acutely and tailed off over time is highly suggestive of a causal
relationship. Our study is a large population-based cohort that
is reasonably representative of the general UK population, and
the size of the cohort gave increased statistical power. In addi-
tion, high-quality data were available on clinical encounters.
CPRD data are routine data captured during clinical care of
patients and are not collected to answer a speciﬁc research ques-
tion, so some misclassiﬁcation of exposures and outcomes is
possible. However, this misclassiﬁcation is likely to be random,
and any bias will have tended to underestimate effects.
Most patients in our study (60%) had no information docu-
menting stroke type; despite the large sample size, this reduced
the power of our study to assess the effect of zoster on stroke
type, although the majority of strokes in adults are likely to be
ischemic in nature. A previous CPRD validation study of stroke
diagnoses demonstrated that nearly in 90% of individuals with
stroke, diagnoses were conﬁrmed reviewing their written medical
records, and stroke incidence rates were similar to other sources
[27, 28]. Zoster has a highly characteristic clinical presentation
and is readily diagnosed by general practitioners; previous studies
have reported positive predictive values of >90% for zoster diag-
noses in administrative and medical record data [29, 30].
Despite efforts to improve capture of herpes zoster ophthal-
micus by looking for acute eye diseases or speciﬁc therapy with-
in 2 weeks of zoster and speciﬁed nonacute eye diseases within
3 months of zoster, some misclassiﬁcation of herpes zoster oph-
thalmicus is likely [31]. The small numbers of individuals we
identiﬁed with herpes zoster ophthalmicus limited power to as-
sess the association between herpes zoster ophthalmicus and
stroke, reducing effect estimate precision.
In conclusion, our study ﬁndings have demonstrated an in-
creased risk of stroke in the ﬁrst 6 months following acute zos-
ter. The risk was higher in individuals with herpes zoster
ophthalmicus. The relatively low prescribing rates of antiviral
treatment need to be improved, as our data suggest that oral an-
tiviral therapy may lead to a reduction in stroke risk following
zoster. Study ﬁndings have important implications for zoster
vaccination programs, which, in addition to reducing incident
zoster and PHN, might have the potential to reduce incident
stroke following zoster.
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